Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2006-10-17
2006-10-17
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093200, C424S093210, C424S093700
Reexamination Certificate
active
07122179
ABSTRACT:
Method for inoculating a vertebrate host against malaria, by administering to the host a livePlasmodiumorganism that is genetically engineered to disrupt a gene whose expression is up-regulated in liver stage parasites and whose function is not required for entry into hose hepatocytes.
REFERENCES:
patent: 4681762 (1987-07-01), Oeschger et al.
patent: 6656479 (2003-12-01), Brake et al.
patent: WO 95/07094 (1995-03-01), None
patent: WO 00/08165 (2000-02-01), None
patent: WO 2004/026903 (2004-04-01), None
patent: WO 2004/045559 (2004-06-01), None
Butler, D., “Mosquito Production Mooted as Fast Track to Malaria Vaccine,”Nature 425:437, Oct. 2, 2003.
Doolan, D.L., and S.L. Hoffman, “The Complexity of Protective Immunity Against Liver-Stage Malaria,”The Journal of Immunology 165:1453-1462, 2000.
Fandeur, T., et al., “Protection of Squirrel Monkeys Against VirulentPlasmodium falciparumInfections by Use of Attenuated Parasites,”Infection and Immunity 60(4):1390-1396, Apr. 1992.
Guerin-Marchand, C., et al., “A Liver-Stage-Specific Antigen ofPlasmodium falciparumCharacterized by Gene Cloning,”Nature 329:164-167, Sep. 10, 1987.
Hoffman, S., “Save the Children,”Nature 430:940-941, Aug. 19, 2004.
Hoffman, S.L., and D.L. Doolan, “Malaria Vaccines-Targeting Infected Hepatocytes,”Nature Medicine 6(11):1218-1219, Nov. 2000.
Hoffman, S.L., et al., “Protection of Humans Against Malaria by Immunization With Radiation-AttenuatedPlasmodium falciparumSporozoites,”The Journal of Infectious Diseases 185:1155-1164, Apr. 15, 2002.
James, S., and L. Miller, “Malaria Vaccine Development: Status Report,” Niaid.nih.gov, Jan. 5, 2001, <http://www.niaid.nih.gov/dmid/malaria/malariavac.htm> [retrieved Oct. 15, 2004].
Kaiser, K., et al., “Differential Transcriptome Profiling IdentifiesPlasmodiumGenes Encoding Pre-Erythrocytic Stage-Specific Proteins,”Molecular Microbiology, 2004, pp. 1221-1232.
Kappe, S.H.I., et al., “PlasmodiumSporozoite Molecular Cell Biology,”Annu. Rev. Cell Dev. Biol. 20:29-59, 2004.
Luke, T.C., and S.L. Hoffman, “Rationale and Plans for Developing a Non-Replicating, Metabolically Active, Radiation-AttenuatedPlasmodium falciparumSporozoite Vaccine,”The Journal of Experimental Biology 206:3803-3808, 2003.
Ménard, R., “Knockout Malaria Vaccine?”Nature 433:113-114, Jan. 13, 2005.
Mueller, A.-K., et al., “PlasmodiumLiver Stage Developmental Arrest by Depletion of a Protein at the Parasite-Host Interface,”PNAS 102(8):3022-3027, Feb. 22, 2005.
“Parasitic and Tropical Infections,”The Jordan Report: Accelerated Development of Vaccines, National Institutes of Health, 2000, pp. 25-30.
Scheller, L., and A.F. Azad, “Maintenance of Protective Immunity Against Malaria by Persistent Hepatic Parasites Derived From Irradiated Sporozoites,”Proc. Natl. Acad. Sci. USA 92:4066-4068, Apr. 1995.
Silvie, O., et al., “Effects of Irradiation onPlasmodium falciparumSporozoite Hepatic Development: Implications for the Design of Pre-Erythrocytic Malaria Vaccines,”Parasite Immunology 24(4):221-223, Apr. 2002.
Suzuki, M., et al., “An Alternative Approach to Malaria Vaccine With a Permanent Attenuated Mutant From a High Virulence Plasmodium Berghei Strain,”Zentralbl. Bakteriol. Mikrobiol. Hyg. 264(3-4):319-325, May 1987. (Abstract provided).
Waters, A.P., et al., “Malaria Vaccines: Back to the Future?,”Science 307:528-530, Jan. 28, 2005.
Worthey, E.A., and P.J. Myler, Invited review, “Protozoan genomes: Gene Identification and Annotation,”International Journal for Parasitology 35:495-512, 2005.
Ménard, R., et al., “Circumsporozoite Protein Is Required for Development of Malaria Sporozoites in Mosquitoes,”Nature 385(6614):336-340, Jan. 1997.
Ménard, R., and C. Janse, “Gene Targeting in Malaria Parasites,”METHODS: A Companion to Methods in Enzymology 13(2):148-157, Oct. 1997.
Matuschewski, K., et al., Infectivity-Associated Changes in the Transcriptional Repertoire of the Malaria Parasite Sporozite Stage,Journal of Biological Chemistry 277(4):41948-41953, Nov. 2002.
Mueller, A.-K., et al., Genetically ModifiedPlasmodiumParasites as a Protective Experimental Malaria Vaccine,Nature 433(7022):164-167, Jan. 13, 2005.
Sultan. A.A., et al., “TRAP Is Necessary for Gliding Motility and Infectivity ofPlasmodium sporozoites,” Cell 90(3):511-522, Aug. 8, 1997.
van Dijk, M.R., et al., “A Central Role for P48/45 in Malaria Parasite Male Gamete Fertility,”Cell 104(1);153-164, Jan. 12, 2001.
Kappe Stefan H. I.
Matuschewski Kai-Uwe C.
Mueller Ann-Kristin
Blöchlinger Karen
Broderick Thomas F.
Christensen O'Connor Johnson & Kindness PLLC
Navarro Mark
Ruprecht-Karls-Universität Heidelberg
LandOfFree
Live genetically attenuated malaria vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live genetically attenuated malaria vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live genetically attenuated malaria vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626567